Bühlmann Laboratories AG   Report issue

For profit Phase 4
Founded: Schönenbuch Switzerland (1976)

Organization Overview

First Clinical Trial
2020
NCT04646187
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Bühlmann Laboratories AG

Active Ingredients

Drugs in Phase 4 Trials (2)

adalimumab (humira) (1 trial)

infliximab (remicade) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 4)

Colitis, Ulcerative (Phase 4)

Crohn Disease (Phase 4)

Inflammatory Bowel Diseases (Phase 4)

Intestinal Diseases (Phase 4)

Ulcer (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 2